Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

ConclusionThese results support the long-term safety and effectiveness of natalizumab. Baseline predictors of NEDA help to inform benefit-risk assessments of natalizumab treatment in JCV-negative patients with early RRMS.Trial RegistrationClinicalTrials.gov identifier NCT01485003.

http://link.springer.com/10.1007/s12325-021-01722-w

Source: Advances in Therapy - May 20, 2021 Category: Drugs & Pharmacology Source Type: research